IMU-838 and Oseltamivir in the Treatment of COVID-19
Status:
Recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
To evaluate whether time-to-improvement is significantly better in IMU-838 plus Oseltamivir
(IONIC Intervention) and standard care vs. Oseltamivir and standard care in adult subjects
with coronavirus disease (COVID-19)
Phase:
Phase 2
Details
Lead Sponsor:
University Hospitals Coventry and Warwickshire NHS Trust